Clinical

Dataset Information

0

A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors: DEEPER


ABSTRACT: Interventions: FOLFOXIRI+Bevacizumab (until 12 courses) 5-FU+Levofolinate+Bevacizumab (after 13 courses) Bevacizumab 5mg/kg/bi-weekly Irinotecan 150mg/m2/bi-weekly Oxaliplatin 85mg/m2/bi-weekly Levofolinate 200mg/m2/bi-weekly 5-FU 2400mg/m2/bi-weekly FOLFOXIRI+Cetuximab (until 12 courses) 5-FU+Levofolinate+etuximab (after 13 courses) Cetuximab (first time) 400 mg/m2/week Cetuximab (after 2nd time) 250 mg/m2/week Irinotecan 150mg/m2/bi-weekly Oxaliplatin 85mg/m2/bi-weekly Levofolinate 200mg/m2/bi-weekly 5-FU 2400mg/m2/bi-weekly Primary outcome(s): DpR: Deepness of Response Study Design: Parallel Randomized

DISEASE(S): Nras Exon 2,3,4),Measurable Advanced Colorectal Cancer With Ras Wild-type ( Kras Exon 2,3,4

PROVIDER: 2633522 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2633714 | ecrin-mdr-crc
| 2613998 | ecrin-mdr-crc
| 2630485 | ecrin-mdr-crc
| 2630804 | ecrin-mdr-crc
| 2630948 | ecrin-mdr-crc
| 2622536 | ecrin-mdr-crc
| 2618714 | ecrin-mdr-crc
| 2621834 | ecrin-mdr-crc
| 2630399 | ecrin-mdr-crc
| 2623247 | ecrin-mdr-crc